

GLAXOSMITHKLINE PLC  
Form 6-K  
February 15, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 15 February 2019

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

GlaxoSmithKline plc (the 'Company')

Conditional Share Awards

On 13 February 2019, the Company granted awards to the Executive Directors and Persons Discharging Managerial Responsibilities (PDMRs) listed below. The awards have been granted in accordance with the rules of the GlaxoSmithKline 2017 Deferred Annual Bonus Plan (DABP) which was approved by shareholders on 4 May 2017.

Executive Directors are required to defer 50% of any bonus earned into Ordinary Shares or ADSs for a period of three years. Other participants are required to defer 25% of any bonus earned into Ordinary Shares or ADSs for the same period.

With effect from 2018, DABP Matching Awards are no longer granted.

The awards of deferred shares (Deferred Bonus Awards) have been granted as conditional awards over ADSs for US participants and as nil-cost options over Ordinary Shares for all other participants.

The numbers of shares shown below are exclusive of dividend reinvestment that will accrue during the deferral period.

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms E Walmsley
  - b) Position/status Chief Executive Officer
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).
  - c) Price(s) and volume(s)
 

| Price(s) | Volume(s) |
|----------|-----------|
| £15.468  | 61,813    |
  - d) Aggregated information n/a (single transaction)
  - e) Date of the transaction 2019-02-13
  - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr H Barron
- b) Position/status Chief Scientific Officer and President, R&D
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

- b) Nature of the transaction Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

- |                           |          |           |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | Price(s) | Volume(s) |
|                           | \$40.53  | 37,120    |

- d) Aggregated information n/a (single transaction)

- e) Aggregated volume Price

- e) Date of the transaction 2019-02-13

- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R Connor
- b) Position/status President, Global Vaccines
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument  
ISIN: GB0009252882

b) Nature of the transaction  
Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

c) Price(s) and volume(s)  
Price(s) Volume(s)  
£15.468 16,223

d) Aggregated information  
Aggregated volume Price  
n/a (single transaction)

e) Date of the transaction  
2019-02-13

f) Place of the transaction  
n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name  
Mr S Dingemans

b) Position/status  
Chief Financial Officer

c) Initial notification/  
amendment  
Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name  
GlaxoSmithKline plc

b) LEI  
5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument  
ISIN: GB0009252882

b) Nature of the transaction  
Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

c) Price(s) and volume(s)  
Price(s) Volume(s)  
£15.468 44,215

d) Aggregated information  
Aggregated volume Price  
n/a (single transaction)

e) Date of the transaction  
2019-02-13

f) Place of the transaction  
n/a

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr J Ford
  - b) Position/status SVP & General Counsel
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument American Depository Shares ('ADSs')  
ISIN: US37733W1053
  - b) Nature of the transaction Deferred Bonus Award of ADSs (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).
  - c) Price(s) and volume(s)
 

| Price(s) | Volume(s) |
|----------|-----------|
| \$40.53  | 3,202     |
  - d) Aggregated information n/a (single transaction)
  - e) Aggregated volume Price
  - f) Date of the transaction 2019-02-13
  - g) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr N Hirons
  - b) Position/status SVP, Global Ethics and Compliance
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction  
 Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

|                           | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | £15.468  | 6,801     |

d) Aggregated information  
 Aggregated volume Price n/a (single transaction)

e) Date of the transaction 2019-02-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr L Miels  
 b) Position/status President, Global Pharmaceuticals

c) Initial notification/  
 amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument  
 Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction  
 Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

|                           | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | £15.468  | 17,252    |

d) Aggregated information  
 Aggregated volume Price n/a (single transaction)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- e) Date of the transaction 2019-02-13
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr B McNamara
- b) Position/status CEO, GSK Consumer Healthcare

- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

American Depositary Shares ('ADSs')

- a) Description of the financial instrument ISIN: US37733W1053

- b) Nature of the transaction Deferred Bonus Award of ADSs (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

- c) Price(s) and volume(s)
 

|          |           |
|----------|-----------|
| Price(s) | Volume(s) |
| \$40.53  | 6,251     |

- d) Aggregated information n/a (single transaction)
- e) Aggregated volume Price

- e) Date of the transaction 2019-02-13
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D Redfern
- b) Position/status Chief Strategy Officer

- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

place where transaction(s) has been conducted

a) Description of the financial instrument  
 Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction  
 Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

c) Price(s) and volume(s)  
 Price(s)      Volume(s)  
 £15.468      15,331

d) Aggregated information  
 Aggregated volume Price      n/a (single transaction)

e) Date of the transaction      2019-02-13

f) Place of the transaction      n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name      Mr R Simard  
 b) Position/status      President, Pharmaceuticals Supply Chain

c) Initial notification/  
 amendment      Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name      GlaxoSmithKline plc  
 b) LEI      5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument  
 Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction  
 Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

c) Price(s) and volume(s)  
 Price(s)      Volume(s)



£15.468 5,540

- d) Aggregated information n/a (single transaction)
- e) Date of the transaction 2019-02-13
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas
- b) Position/status SVP, Human Resources
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

- c) Price(s) and volume(s) Price(s) Volume(s)  
£15.468 13,098

- d) Aggregated information n/a (single transaction)
- e) Date of the transaction 2019-02-13
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr P Thomson
- b) Position/status President, Global Affairs
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

Ordinary shares of 25 pence  
 each ('Ordinary Shares')

- a) Description of the financial instrument

ISIN: GB0009252882

- b) Nature of the transaction

Deferred Bonus Award of  
 Ordinary Shares (under the  
 GlaxoSmithKline 2017  
 Deferred Annual Bonus  
 Plan).

- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £15.468  | 8,972     |

- d) Aggregated information n/a (single transaction)  
 Aggregated volume Price

- e) Date of the transaction 2019-02-13

- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms K Terrell  
 b) Position/status Chief Digital & Technology  
 Officer

- c) Initial notification/  
 amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction  
 platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

- Details of the transaction(s): section to be repeated for (i) each type  
 3. of instrument; (ii) each type of transaction; (iii) each date; and (iv)  
 each place where transaction(s) has been conducted

American Depositary Shares  
 ('ADSs')

- a) Description of the financial instrument

ISIN: US37733W1053

- b) Nature of the transaction

Deferred Bonus Award of  
 ADSs (under the  
 GlaxoSmithKline 2017  
 Deferred Annual Bonus  
 Plan).

|  | Price(s)                 | Volume(s) |
|--|--------------------------|-----------|
| c) Price(s) and volume(s)                            | \$40.53                  | 7,899     |
| d) Aggregated information<br>Aggregated volume Price | n/a (single transaction) |           |
| e) Date of the transaction                           | 2019-02-13               |           |
| f) Place of the transaction                          | n/a                      |           |

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 15, 2019

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc